Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02587650
Title Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University of California, San Francisco
Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST